Daiichi’s Anti-Clotting Drug Hit By New U.S. FDA Delay
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo's Effient (prasugrel) anti-clotting drug, which it is developing with U.S.-based Eli Lilly, has hit a new snag in obtaining U.S. FDA approval. The agency told the companies it had not completed its review yet, but did not say how much longer it would take. The approval had been expected Sept. 26. The agency already had delayed its review by three months. It provided no additional information. The drug is expected to be a $2 billion-a-year blockbuster for the two. (Click here for more